3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
50
Lung Neoplasms
13
Neoplasms
8
Melanoma
6
Neoplasm Metastasis
5
Head and Neck Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Breast Neoplasms
4
Urinary Bladder Neoplasms
3
Triple Negative Breast Neoplasms
3
Stomach Neoplasms
3
Ovarian Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Merkel Cell
3
Carcinoma, Hepatocellular
3
Uterine Cervical Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Mesothelioma, Malignant
2
Gastrointestinal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Large Cell
2
Carcinoma, Basal Cell
2
Brain Neoplasms
2
Advanced Non-Small Cell Lung Cancer
2
Adenocarcinoma
2
Vaccinia
1
Uterine Neoplasms
1
Interventions
Carboplatin
15
Pemetrexed
8
Paclitaxel
6
pembrolizumab
5
osimertinib
4
atezolizumab
4
Gemcitabine
4
Erlotinib Hydrochloride
4
entinostat
3
durvalumab
3
Cisplatin
3
selpercatinib
2
pralsetinib
2
camrelizumab
2
apatinib
2
Vinorelbine
2
Radiosurgery
2
Nivolumab
2
Injections
2
Gefitinib
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
toripalimab
1
taletrectinib
1
sotorasib
1
sintilimab
1
repotrectinib
1
pegylated granulocyte colony-stimulating factor
1
patritumab
1
necitumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thoracic Neoplasms
×
cemiplimab
×
Thoracic
×
Clear all
NCT06917573
2025-11-19
PALACE
Fundación GECP
Phase 2
Recruiting
63 enrolled